2026-09-29T11:41:16.000Z · 4 days ago Decoy Therapeutics’ human coronaviruses candidate shows positive PK data
Sep 29, 2026, 7:30 AM EDT · 4 days ago Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program
Sep 22, 2026, 6:14 PM EDT · 11 days ago Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release
Sep 22, 2026, 12:50 PM EDT · 11 days ago Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules
2026-09-22T11:35:09.000Z · 11 days ago Decoy Therapeutics to explore pan-filovirus program via FDA Animal Rule pathway
Sep 22, 2026, 7:30 AM EDT · 11 days ago Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding
Sep 8, 2026, 9:00 AM EDT · 25 days ago Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
Aug 3, 2026, 9:00 AM EDT · 2 months ago Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform
2026-07-27T13:11:19.000Z · 2 months ago Decoy Therapeutics’ D-MAV platform shows inhibition of Ebola Zaire virus
Jul 27, 2026, 9:00 AM EDT · 2 months ago Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
Jul 15, 2026, 9:24 AM EDT · 2 months ago Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors
2026-07-10T20:30:13.000Z · 2 months ago Decoy Therapeutics registers to sell 3.77M shares of common stock for holders
2026-06-29T13:35:22.000Z · 3 months ago Decoy Therapeutics Inc trading halted, volatility trading pause
Jun 26, 2026, 8:11 PM EDT · 3 months ago Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
2026-06-15T10:16:08.000Z · 3 months ago Decoy Therapeutics files to sell 808,000 shares of common stock for holders
2026-06-09T15:45:30.000Z · 3 months ago Decoy Therapeutics Inc trading halted, volatility trading pause
Jun 8, 2026, 8:00 AM EDT · 3 months ago Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London
Jun 3, 2026, 8:00 AM EDT · 4 months ago Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors
Jun 1, 2026, 7:00 AM EDT · 4 months ago Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic
May 26, 2026, 8:15 AM EDT · 4 months ago Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board
Apr 27, 2026, 8:45 AM EDT · 5 months ago Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston
Apr 9, 2026, 8:36 AM EDT · 5 months ago Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline
Apr 6, 2026, 9:15 AM EDT · 6 months ago Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026
Apr 2, 2026, 9:00 AM EDT · 6 months ago Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
2026-03-11T12:36:44.000Z · 6 months ago Decoy Therapeutics enters collaboration with Quantori GOOG GOOGL
Mar 11, 2026, 8:30 AM EDT · 6 months ago Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform
Feb 11, 2026, 9:00 AM EST · 7 months ago Decoy Therapeutics Joins Webull Corporate Connect Service Platform
Feb 5, 2026, 9:15 AM EST · 8 months ago Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Feb 4, 2026, 9:02 AM EST · 8 months ago Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement
Jan 13, 2026, 8:15 AM EST · 8 months ago Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform
Jan 7, 2026, 8:45 AM EST · 8 months ago Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
Dec 19, 2025, 11:12 AM EST · 9 months ago Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Dec 18, 2025, 7:50 AM EST · 9 months ago Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform
Dec 1, 2025, 8:00 AM EST · 10 months ago Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study
Nov 19, 2025, 2:42 PM EST · 10 months ago Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”
Nov 13, 2025, 8:45 AM EST · 10 months ago Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger
Nov 11, 2025, 9:18 AM EST · 10 months ago Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering
Oct 13, 2025, 8:45 AM EDT · 11 months ago Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements
Sep 9, 2025, 8:00 AM EDT · 1 year ago Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Aug 14, 2025, 8:30 AM EDT · 1 year ago Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split
Jul 14, 2025, 8:30 AM EDT · 1 year ago Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard
Jul 9, 2025, 8:30 AM EDT · 1 year ago Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies
Apr 16, 2025, 8:00 AM EDT · 1 year ago Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
Mar 24, 2025, 8:00 AM EDT · 1 year ago Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update
Feb 3, 2025, 8:00 AM EST · 1 year ago Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers
Jun 12, 2024, 8:00 AM EDT · 2 years ago Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split
Mar 22, 2024, 4:05 PM EDT · 2 years ago Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Jan 3, 2024, 8:30 AM EST · 2 years ago Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
Nov 7, 2023, 8:30 AM EST · 2 years ago Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
Aug 10, 2023, 4:05 PM EDT · 3 years ago Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update
Jul 11, 2023, 8:30 AM EDT · 3 years ago Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients
Jun 12, 2023, 8:00 AM EDT · 3 years ago Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress
May 16, 2023, 4:05 PM EDT · 3 years ago Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
May 12, 2023, 8:00 AM EDT · 3 years ago Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
May 11, 2023, 8:00 AM EDT · 3 years ago Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update